Hologic announced its third quarter fiscal 2025 financial results, reporting net income of 86 cents per share and adjusted earnings of $1.08 per share, surpassing Wall Street expectations. Revenue reached $1.02 billion, an increase of 1.2% year-over-year, also topping market estimates.
Following the strong performance, Hologic raised its annual profit forecast, anticipating robust demand for its molecular diagnostic devices and surgical products. The company's guidance for the next quarter's revenue is projected to be around $1.04 billion.
This upward revision in the profit outlook reflects confidence in the company's core business segments and operational execution. The positive earnings and guidance update are significant indicators for investors regarding Hologic's financial trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.